SCHEMBL24739338

SCHEMBL24739338

CCOC(=O)Cc1cn2cc(C3CC3)cc(Br)c2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.38
MEN1 O00255 6/20 0.38
KMT2A Q03164 6/20 0.38
ALDH1A1 P00352 5/20 0.38
TDP1 Q9NUW8 5/20 0.38
MAPT P10636 4/20 0.38
THRB P10828 3/20 0.38
FPR1 P21462 3/20 0.36
HSD17B10 Q99714 3/20 0.36
POLB P06746 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
RECQL P46063 1/20 0.36
LMNA P02545 2/20 0.35
JAK2 O60674 1/20 0.35
PAK4 O96013 1/20 0.35
NTRK1 P04629 1/20 0.35
LCK P06239 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21354863 0.84 KDM4E (0.44) KDM4EKMT2AALDH1A1MAPTTHRB
SCHEMBL29137007 0.83 KDM4E (0.39) KDM4EALDH1A1TDP1THRBPOLB
SCHEMBL24737435 0.81 KDM4E (0.45) KDM4EALDH1A1MAPTHSD17B10POLB
SCHEMBL27033575 0.81 KDM4E (0.37) KDM4EMEN1KMT2AALDH1A1TDP1
SCHEMBL31658609 0.80 DRD2 (0.34)
SCHEMBL29136933 0.80 GRM5 (0.31) ALDH1A1SMN1; SMN2
SCHEMBL29302417 0.80 DPP4 (0.39) KDM4EMEN1KMT2AALDH1A1TDP1
SCHEMBL24739345 0.79 KMT2A (0.35) KDM4EMEN1KMT2AALDH1A1TDP1
SCHEMBL29303249 0.79 MAPT (0.36) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL21355570 0.79 ALDH1A1 (0.46) MEN1KMT2AALDH1A1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-07-11 US disclosed
EP-4308230-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 EP disclosed
CN-117355521-A Heteroaryl inhibitors of plasma kallikrein 武田药品工业株式会社 2024-01-05 CN disclosed
WO-2022197758-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed
WO-2022197758-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228488-A1 HETEROARYL INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK5, KLK1 KDM4E 796/4885MEN1 1290/4885KMT2A 1222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.